FULVESTRANT
Endometrial Neoplasm
Atavistik Bio, IncSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Endometrial Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zanidatamab Haihua Yuan | Phase 2 | CCC |
Trastuzumab Duocarmazine QuantumLeap Healthcare Collaborative | Phase 1 | CC |
Atv-1601 Atavistik Bio, Inc | Phase 1 | CC |
Same molecule, other indications
FULVESTRANT is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →